NASDAQ
Kyverna Therapeutics, Inc. (KYTX) has a price/fcf ratio of -2.71x as of Monday, May 25, 2026. This represents a 97.52% increase compared to its 12-month average of -109.08x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.
No price data available for this timeframe.